ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Scleroderma, Localized"

  • Abstract Number: 1366 • ACR Convergence 2022

    Developing a Mobile App to Facilitate Disease Activity Assessment in Localized Scleroderma

    Suzanne Li1, Xiaohu Li2, Tara Lozy3 and Jiajun Chen4, 1Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, West Orange, NJ, 2Stevens Institute of Technology, Hoboken, NJ, 3Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, 4One Node Lab, League City, TX

    Background/Purpose: Juvenile localized scleroderma (jLS) is an inflammatory and fibrosing disease that causes severe morbidity (e.g., hemiatrophy, arthropathy, seizures), with functional impairment found in >25%…
  • Abstract Number: 0772 • ACR Convergence 2021

    Pediatric Craniofacial Scleroderma: Assessing Handheld 3D Stereophotogrammetric Imaging Feasibility and Reliability

    Daniel Glaser1, Kaila Schollaert-Fitch2, Christopher Liu1, Jesse Goldstein1 and Kathryn Torok2, 1UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Craniofacial scleroderma (Cf-LS), also known as Parry-Romberg Syndrome or scleroderma en coup de sabre, is a subtype of localized scleroderma (morphea). Diagnosis and monitoring…
  • Abstract Number: 0781 • ACR Convergence 2021

    Long-Term Follow-up of Juvenile Localized Scleroderma Patients Treated with Methotrexate-Based Standardized Regimens (Consensus Treatment Plans)

    Suzanne Li1, Aaron Thammavongxay2, Maria Ibarra3, Kathryn Torok4, Polly Ferguson5, C Egla Rabinovich6, Robert Fuhlbrigge7, Katie Stewart8, Elena Pope9, Ronald Laxer10, Sandy Hong11, Thomas Mason12, Mara Becker13, Gloria Higgins14, Fatma Dedeoglu15 and for the CARRA Legacy Registry16, 1Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, West Orange, NJ, 2Bergen Academies, Hackensack, NJ, 3Children's Mercy Hospital, Kansas City, MO, 4University of Pittsburgh, Pittsburgh, PA, 5University of Iowa Carver College of Medicine, Iowa City, IA, 6Duke Childrens Hospital & Health Center, Durham, NC, 7University of Colorado, Denver, CO, 8UT Southwestern, Dallas, TX, 9Hospital for Sick Kids, Toronto, ON, Canada, 10SickKids, Toronto, ON, Canada, 11University of Iowa Stead Family Children's Hospital, Iowa City, IA, 12Mayo Clinic, Rochester, MN, 13Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, NC, 14Ohio State University, Columbus, OH, 15Boston Children's Hospital, Boston, MA, 16Childhood Arthritis and Rheumatology Research Alliance, Milwaukee, WI

    Background/Purpose: Juvenile localized scleroderma (jLS) is a rare chronic inflammatory and fibrosing disease associated with a high risk for morbidity in children. Methotrexate (MTX) has…
  • Abstract Number: 0979 • ACR Convergence 2021

    Autoantibody Testing in Juvenile Localized Scleroderma and Systemic Sclerosis: Comparing Antibody Profiles and Clinical Correlations

    Jonathan Li1, Emily Mirizio1, Katherine Buhler2, May Choi3, Haiyan Hou2, Giffin Werner1, Anwesha Sanyal1, Kaila Schollaert-Fitch1, Marvin Fritzler2 and Kathryn Torok1, 1University of Pittsburgh, Pittsburgh, PA, 2University of Calgary, Calgary, AB, Canada, 3Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada

    Background/Purpose: Pediatric scleroderma encompasses juvenile onset localized scleroderma (jLS) and juvenile onset systemic sclerosis (jSSc), both of which present with varied cutaneous fibrosis and systemic…
  • Abstract Number: 1856 • ACR Convergence 2021

    Serum IFN Score Predicts Long Term Outcome in Limited Cutaneous SSc

    Ranjitha Karanth1, Giuseppina Abignano2, Vishal Kakkar2, Rebecca Ross2, Christopher Denton3 and Francesco Del Galdo2, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, LTHT, Leeds, United Kingdom, 2University of Leeds, Leeds, United Kingdom, 3University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom

    Background/Purpose: Limited cutaneous systemic sclerosis (lcSSc) carries a highly variable prognosis and to date there are no stratification tools to predict clinical outcomes. Evidence suggests…
  • Abstract Number: 0175 • ACR Convergence 2020

    Identifying Immuno-phenotypes in Juvenile Localized Scleroderma with RNA Sequencing

    Christina Schutt1, Emily Mirizio2, Kaila Schollaert-Fitch2, Claudia Salgado3, Miguel Reyes-Mugica3 and Kathryn Torok2, 1University of Pittsburgh Medical Center, Pittsburgh, PA, 2University of Pittsburgh, Pittsburgh, PA, 3University of Pittsburgh Medical Center, Pittsburgh

    Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease of the skin and underlying tissue characterized by an early inflammatory infiltrate followed by fibrosis and…
  • Abstract Number: 0394 • ACR Convergence 2020

    Prevalence of a Diagnosis of Osteopenia/Osteoporosis Amongst Patients with Systemic Sclerosis and Identification of Associated Clinical Factors

    Guanying Wang1, Diane Mar2, Joy Wu3, Julia Simard4, Rita Popat1 and Lorinda Chung5, 1Department of Epidemiology & Population Health, Stanford University School of Medicine, Palo Alto, CA, 2Stanford Department of Immunology/Rheumatology, Palo Alto, CA, 3Department of Medicine, Division of Endocrinology, Stanford University School of Medicine, Palo Alto, CA, 4Stanford Medicine, Stanford, CA, 5Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA

    Background/Purpose: This study aims to determine the prevalence of a diagnosis of osteopenia/osteoporosis (OP) in systemic sclerosis (SSc) patients and to identify the clinical and…
  • Abstract Number: 0916 • ACR Convergence 2020

    Validating Autoantibody Associations and Clinical Impact of Severe Gastrointestinal Involvement in Systemic Sclerosis

    Fiza Ahmed1, Svetlana Nihtyanova1, Stamatia Chatzinikolaou2, Voon Ong1, Charles Murray2 and Christopher Denton3, 1Centre for Rheumatology, Royal Free Campus, UCL Division of Medicine, UK, London, United Kingdom, 2Department of Gastroenterology, Royal Free London Foundation Trust, UK, London, United Kingdom, 3University College London, London, United Kingdom

    Background/Purpose: Patients with systemic sclerosis (SSc) frequently experience gastrointestinal (GI) symptoms, ranging from mild to debilitating in severity. Better prediction of those most at risk…
  • Abstract Number: 1035 • ACR Convergence 2020

    Study of Ocular Sarcoidosis and Clusters of Clinical Associations in a Series of 383 Patients with Systemic Sarcoidosis from a Single Hospital

    Inigo Gonzalez-Mazon1, Carmen Alvarez-Reguera2, Lara Sanchez-Bilbao2, David Martinez-Lopez3, Alba Herrero Morant2, Jorge Javier Gaitan-Valdizan4, Raul Fernandez-Ramon2, Rosalia Demetrio-Pablo2 and Ricardo Blanco2, 1Hospital Universitario Marques de Valdecilla, Bezana, Spain, 2Hospital Universitario Marques de Valdecilla, Santander, Spain, 3Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, 4Hospital Universitario Marqués de Valdecilla, Santander, Spain

    Background/Purpose: Sarcoidosis is an inflammatory disease which can affect multiple organs. The most frequent affected organs are lungs, skin and eyes. Ocular involvement is a…
  • Abstract Number: 1397 • ACR Convergence 2020

    Clinical and Demographic Features of Morphea Patients with Mucocutaneous Involvement: A Cross Sectional Study from the Morphea of Adults and Children Cohort

    Smriti Prasad1, Samantha Black2, Shivani Sharma3 and Heidi Jacobe1, 1University of Texas Southwestern Medical Center, Dallas, TX, 2The University of Texas Southwestern Medical Center, Dallas, TX, 3University of Texas Southwestern, Dallas, TX

    Background/Purpose: Morphea is an autoimmune skin condition that produces skin and soft tissue sclerosis. While clinical manifestations of morphea have been well-described, mucocutaneous findings such…
  • Abstract Number: 1560 • ACR Convergence 2020

    Measuring Asymmetry in Facial Morphea via 3D Stereophotogrammetry

    Laila Abbas1, Jennifer Day2 and Heidi Jacobe3, 1UT Southwestern Medical Center, Dallas, TX, 2University of Colorado, Denver, CO, 3University of Texas Southwestern Medical Center, Dallas, TX

    Background/Purpose: Morphea is an autoimmune disorder causing sclerosis and inflammation of the skin and subcutaneous tissue. Facial morphea can cause substantial disfigurement and negative impact on quality of life. Existing clinical measures such…
  • Abstract Number: 2038 • ACR Convergence 2020

    Characterizing Morphea Subsets Using a Multi-center, Prospective, Cross-sectional Analysis

    Jane Zhu1, Smriti Prasad2, Kaila Schollaert-Fitch3, Robert Haley4, Kathryn Torok3 and Heidi Jacobe2, 1UT Southwestern Medical Center, Dallas, 2University of Texas Southwestern Medical Center, Dallas, TX, 3University of Pittsburgh, Pittsburgh, PA, 4University of Texas Southwestern Medical Center, Dallas

    Background/Purpose: Morphea, or localized scleroderma, is an inflammatory condition of the skin and soft tissue that results in excessive collagen deposition, often producing permanent functional…
  • « Previous Page
  • 1
  • 2
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology